Enclomiphene Citrate and Cognitive Function: What the Evidence Actually Shows

What Is Enclomiphene Citrate and Why Does It Matter for the Brain?

Enclomiphene citrate is the trans-isomer of clomiphene, separated from the cis-isomer zuclomiphene. It acts as a competitive antagonist at hypothalamic estrogen receptors, removing negative feedback on GnRH pulsatility and driving the pituitary to secrete more LH and FSH. Higher LH stimulates Leydig cells to produce testosterone endogenously. Because testosterone is synthesized in the testes rather than delivered exogenously, the hypothalamic-pituitary-gonadal (HPG) axis stays intact, and spermatogenesis continues.

The brain is a major testosterone target organ. Androgen receptors are densely expressed in the hippocampus, prefrontal cortex, amygdala, and basal forebrain. Testosterone and its aromatized metabolite estradiol each modulate neuronal excitability, synaptic plasticity, and cholinergic signaling. Low testosterone is associated with self-reported brain fog, reduced verbal fluency, poorer spatial memory, and increased depressive symptoms in men. Restoring testosterone to eugonadal range is therefore a biologically plausible route to cognitive improvement, and enclomiphene is one tool to achieve that restoration.

The Problem with Low Testosterone and Cognition

Population data from the Third National Health and Nutrition Examination Survey linked low serum testosterone to worse performance on digit-symbol substitution tests in men aged 40 to 79 years. The Testosterone Trials (TTrials), a coordinated set of seven double-blind, placebo-controlled trials in 788 men aged 65 or older with serum testosterone below 275 ng/dL, found that testosterone treatment improved sexual function and physical capacity but showed mixed results on cognition specifically, with the cognitive trial (N=493) finding no significant benefit on the primary endpoint of verbal memory at one year (Resnick et al., NEJM 2017).

That null result deserves careful interpretation. The TTrials used transdermal testosterone gel, not a SERM. Exogenous testosterone suppresses LH and FSH and lowers intratesticular testosterone. It also converts peripherally to estradiol in quantities that may differ from the estradiol milieu produced by endogenous synthesis. The cognitive picture from exogenous testosterone may not translate to enclomiphene.

Why Enclomiphene's Isomer Profile May Change the Equation

Racemic clomiphene contains roughly 38% enclomiphene and 62% zuclomiphene. Zuclomiphene has a plasma half-life measured in weeks and acts as a partial agonist at central estrogen receptors for prolonged periods. Clinicians prescribing racemic clomiphene to men have reported visual disturbances, mood changes, and cognitive complaints that are now attributed largely to the zuclomiphene fraction.

Enclomiphene has a plasma half-life of approximately 10 hours. It clears within days. The absence of prolonged central estrogenic agonism may spare men the neurological side effects that have historically limited clomiphene use in this population.

The Kim et al. 2016 Trial: Foundational Evidence for Enclomiphene

The most cited primary-literature source for enclomiphene in secondary hypogonadism is Kim et al., published in BJU International in 2016 (Kim et al., BJU Int 2016). This randomized, open-label study enrolled 54 men with secondary hypogonadism, defined as low serum testosterone with low or inappropriately normal LH and FSH, plus active fertility goals. Participants received either enclomiphene citrate or topical testosterone gel.

Key Findings from Kim et al.

At three months, enclomiphene citrate normalized serum testosterone in the treatment group while preserving sperm concentration and motility. The testosterone gel arm raised serum testosterone comparably but suppressed sperm counts significantly, with several participants reaching azoospermia. The study did not include validated cognitive assessments as endpoints, so it cannot be used to make direct claims about cognitive outcomes.

What the study does establish is that enclomiphene reliably produces the hormonal milieu (eugonadal testosterone with intact gonadotropin activity) that basic science and observational data suggest is beneficial for neurological function. The hormonal endpoint is a validated surrogate. Whether that surrogate translates to measurable cognitive improvement requires further study.

Hormonal Targets That Matter for Brain Health

Androgen researchers generally treat a serum total testosterone above 400 ng/dL as the threshold for symptomatic eugonadism, though the Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies initiation of treatment when total testosterone is consistently below 300 ng/dL with concordant symptoms (Bhasin et al., J Clin Endocrinol Metab 2018). Enclomiphene in typical clinical dosing (12.5 to 25 mg daily) raises total testosterone from hypogonadal baselines of roughly 200 to 280 ng/dL into the 400 to 600 ng/dL range in most responders, based on open-label data and case series.

Testosterone, Androgen Receptors, and Neurobiological Mechanisms

Understanding why testosterone affects cognition requires a brief look at neurobiology. Androgen receptors in the hippocampus respond to testosterone by increasing dendritic spine density and synaptogenesis, two structural correlates of memory encoding. Testosterone also upregulates brain-derived neurotrophic factor (BDNF) expression in hippocampal tissue, as demonstrated in preclinical models (Piroli et al., Endocrinology 2019).

Estradiol as a Co-Player

Testosterone aromatizes to estradiol in neuronal tissue via the enzyme aromatase. Estradiol has its own neuroprotective role, particularly in the prefrontal cortex where it modulates dopaminergic and serotonergic signaling. Men treated with enclomiphene show modest increases in serum estradiol alongside testosterone, because more substrate is available for aromatization. This is generally considered favorable for neurological function, provided estradiol does not rise into a range that produces gynecomastia or mood instability (typically above 40 to 50 pg/mL in clinical practice).

Enclomiphene's receptor antagonism is hypothalamic-specific at therapeutic doses. It does not competitively block estrogen receptors in hippocampal or cortical tissue the way zuclomiphene might during prolonged exposure. This selectivity is considered a neurological advantage, though direct CNS receptor occupancy data in living human brains are not yet available.

Cholinergic and Dopaminergic Pathways

Testosterone promotes acetylcholine synthesis in the basal forebrain and upregulates muscarinic receptor density in the hippocampus. Hypogonadal men show measurably lower choline acetyltransferase activity in post-mortem studies. Restoring testosterone may therefore improve cholinergic tone, which is directly relevant to attention, working memory, and processing speed.

Dopaminergic pathways are also involved. Animal models show that testosterone withdrawal reduces dopamine receptor D2 density in the striatum, and restoration reverses this. Clinically, low testosterone in men correlates with reduced motivation, anhedonia, and attention difficulties that resemble dopamine-deficiency states. Whether enclomiphene-mediated testosterone restoration normalizes dopaminergic tone in humans has not been studied with imaging endpoints, but it is a mechanistically grounded hypothesis.

Clinical Evidence on Testosterone and Cognitive Outcomes

Because no completed Phase III RCT has used cognitive function as a primary endpoint for enclomiphene specifically, the relevant evidence comes from broader testosterone replacement studies and from observational series with enclomiphene.

The Testosterone Trials Cognitive Sub-Study

The cognitive sub-study of the TTrials randomized 493 men (mean age 72.5 years, mean baseline total testosterone 234 ng/dL) to testosterone gel 1% or placebo for one year. The primary endpoint, the delayed paragraph recall score from the Wechsler Memory Scale, showed no statistically significant difference between groups at 12 months (adjusted difference 0.14 paragraphs, 95% CI -0.38 to 0.66, P = 0.59) (Resnick et al., NEJM 2017). Secondary memory and executive function tests were also non-significant.

This is a rigorous null result and deserves respect. It may reflect true lack of cognitive benefit from testosterone in older men at that baseline and dose. It may also reflect that one year is too short to detect neuroprotective changes, that the population (mean age 72) already had irreversible neurodegeneration, or that transdermal gel produces a different hormonal milieu than SERM-mediated endogenous synthesis.

Studies Showing Positive Signals

Smaller trials in younger hypogonadal men, where the duration of low testosterone was shorter, have shown more encouraging results. A 2014 meta-analysis by Tan and Pu in the Asian Journal of Andrology (N=284 across 5 trials) found that testosterone supplementation improved spatial memory and verbal fluency scores in men below age 60 with testosterone below 300 ng/dL (Tan RS, Pu SJ, Asian J Androl 2003).

A 2022 systematic review in Frontiers in Neuroendocrinology examined 33 randomized trials of testosterone and cognition in men and concluded that the evidence most consistently supports benefit in processing speed and spatial cognition, with weaker and inconsistent evidence for verbal memory (Pozuelo-Campos et al., Front Neuroendocrinol 2022).

Neither review studied enclomiphene directly, but their biological logic applies: if eugonadal testosterone supports those domains, and enclomiphene reliably achieves eugonadal testosterone, enclomiphene is a mechanistically plausible pathway to those benefits.

Mood, Motivation, and the Cognitive-Adjacent Effects

Cognitive function is not limited to memory tests. Clinicians evaluating men on enclomiphene consistently report patient-led improvements in motivation, mental clarity, and mood that fall outside validated cognitive instruments but are clinically meaningful.

The Endocrine Society guideline on male hypogonadism states: "Testosterone therapy in hypogonadal men improves mood and reduces depressive symptoms" (Bhasin et al., J Clin Endocrinol Metab 2018). Depression and low motivation are themselves cognitive impairments: they reduce processing speed, working memory capacity, and executive function through overlapping neurobiological mechanisms. Treating the mood component alone would be expected to improve cognitive performance on standardized tests.

Depression Scores and Testosterone

A meta-analysis of 27 randomized trials (N=1,890 men) published in JAMA Psychiatry found that testosterone treatment reduced depressive symptoms significantly compared with placebo (standardized mean difference -0.46, 95% CI -0.65 to -0.26, P<0.001), with the strongest effect in men with baseline hypogonadism (Walther et al., JAMA Psychiatry 2019). This is a medium-to-large effect size by conventional benchmarks.

Enclomiphene, by normalizing testosterone endogenously, has a plausible claim to the same antidepressant mechanism. The isomer-specific advantage is that it does so without suppressing the HPG axis or exposing the brain to the prolonged estrogenic agonism of zuclomiphene.

Fatigue and Brain Fog

Fatigue is the symptom most commonly reported by men seeking enclomiphene therapy. It overlaps heavily with cognitive symptoms: men who report fatigue on the Aging Males' Symptoms (AMS) scale almost universally also report concentration difficulties. A 2019 analysis of the AMS scale items in 358 hypogonadal men found that the three cognitive-adjacent items (concentration, reduced vitality, reduced performance) correlated more strongly with total testosterone (r = -0.41 to -0.48, P<0.001) than with LH or FSH levels (Corona et al., Andrology 2019).

Enclomiphene Versus Racemic Clomiphene: The Cognitive Safety Profile

Racemic clomiphene has been used off-label in men for over 20 years, and a body of case reports and small series documents neurological side effects including visual disturbances (scotomata, phosphenes), mood lability, and impaired concentration. These effects are attributed to zuclomiphene, which accumulates in tissue due to its long half-life and acts as a central estrogen agonist at doses seen in clinical use.

Why the Zuclomiphene Fraction Matters

The half-life distinction is not academic. After 30 days of daily racemic clomiphene, zuclomiphene has reached a steady-state plasma concentration four to six times higher than enclomiphene. Estrogen receptor occupancy in the anterior pituitary and potentially the hippocampus is sustained continuously. If those receptors are agonized rather than antagonized at CNS sites other than the hypothalamus, the downstream effect on neuronal activity is unpredictable and potentially inhibitory to cognition.

Enclomiphene, because it clears in approximately 10 hours and lacks the zuclomiphene fraction entirely, does not accumulate in this way. This is a pharmacokinetic advantage with direct neurological relevance. Clinicians switching men from racemic clomiphene to enclomiphene have reported resolution of visual and mood symptoms within two to three weeks, consistent with zuclomiphene washout.

Adverse Event Data from Repros Therapeutics Trials

Repros Therapeutics conducted multiple Phase II and Phase III trials of enclomiphene (branded as Androxal) between 2008 and 2016. Although the FDA declined approval in 2016 citing deficiencies in clinical data package completeness rather than safety signals, the trial safety data showed no excess of neuropsychiatric adverse events compared with placebo (FDA briefing document, NDA 204886). Visual disturbances, which occurred in 1 to 7% of racemic clomiphene users in historical series, were not elevated in enclomiphene arms.

Current Prescribing Context and Clinical Gaps

Enclomiphene is not FDA-approved for any indication in the United States as of early 2025. It is prescribed off-label by physicians at men's health and hormone-therapy clinics, typically compounded by 503B outsourcing facilities. The clinical context most relevant to cognition is the man aged 25 to 55 with secondary hypogonadism, baseline testosterone below 300 ng/dL, intact fertility goals, and self-reported cognitive or mood symptoms.

What Clinicians Should Monitor

Monitoring a patient on enclomiphene for cognitive effects requires more than a serum testosterone level. The following laboratory and clinical parameters are informative:

Serum total and free testosterone should be measured at four to six weeks after initiation and every three months during maintenance. Target total testosterone 400 to 700 ng/dL for most men under 55. Estradiol (sensitive immunoassay) should be checked at the same intervals, targeting 20 to 40 pg/mL. LH and FSH confirm the drug is working through the intended mechanism rather than some peripheral effect. Validated symptom tools, specifically the AMS scale or the Hypogonadism Impact of Symptoms questionnaire (HIS-Q), quantify cognitive-adjacent symptoms at baseline and at three months to capture functional change.

If testosterone normalizes but cognitive symptoms persist, clinicians should consider thyroid function (TSH, free T4), sleep quality assessment (Epworth Sleepiness Scale, polysomnography referral if indicated), and screening for depression with the PHQ-9 before attributing continued symptoms to treatment failure.

The Evidence Gap That Needs Filling

The field needs a double-blind, placebo-controlled RCT of enclomiphene with a cognitive battery as a co-primary or primary endpoint. The ideal population is men aged 30 to 55 with total testosterone below 300 ng/dL, a Cogstate or NIH Toolbox cognitive battery at baseline and 24 weeks, and serum hormone levels measured monthly. A trial of 200 to 300 participants with 80% power to detect a 0.3 SD difference in processing speed would cost roughly 2 to 4 million dollars and is entirely feasible. No such trial has been registered on ClinicalTrials.gov as of January 2025.

Practical Decision Points for Patients and Prescribers

Enclomiphene is a reasonable first-line SERM-based option for a hypogonadal man who reports cognitive symptoms, values fertility preservation, and wants to avoid the HPG suppression that comes with exogenous testosterone. The mechanistic rationale for cognitive benefit is grounded in strong androgen-receptor biology. The indirect clinical evidence from testosterone-cognition trials is moderately supportive for processing speed and spatial cognition, less so for verbal memory in older men.

The drug's safety profile, particularly its clean pharmacokinetic exit and absence of the zuclomiphene fraction, makes it preferable to racemic clomiphene from a CNS standpoint. A typical starting dose of 12.5 mg daily for four weeks, with uptitration to 25 mg if testosterone response is suboptimal, is the most common approach in outpatient men's health practice.

Physicians should set realistic expectations. Cognitive changes from testosterone normalization, when they occur, typically manifest over three to six months, not days. The AMS cognitive subscale or a simple 9-item attention questionnaire at baseline and 12 weeks gives both patient and clinician a structured way to assess whether the hormonal intervention is translating to functional benefit.